Abstract
ObjectiveCorrelation between BRCA1/2 (BRCA) pathogenic variants and the response to poly (ADP-ribose) polymerase inhibitors (PARPi) has been recognized in patients with ovarian cancer. Moreover, data on the clinical implications of...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have